Calliditas submits draft registration statement for the listing of ADSs in the U.S.
Calliditas Therapeutics AB (publ) (“Calliditas” or the “Company”) today announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”) relating to a potential initial public offering of American Depositary Shares (“ADSs”) in the U.S. (a “U.S. IPO”) representing Calliditas’ common shares and listing of ADSs on the Nasdaq Stock Market (“Nasdaq”). The number of ADSs that may be offered, the number of underlying common shares that may be issued and the price for such instruments have not yet been determined.